Group 1 - The company held a half-year performance and cash dividend briefing on September 2, 2025, attended by key executives including the chairman and financial director [1][2]. - The company reported a revenue of 3,981,572,232.95 yuan for 2024, a decrease of 10.77% compared to 2023's revenue of 4,462,348,636.07 yuan [4]. - For the first half of 2025, the company achieved a revenue of 1.74 billion yuan, a decrease of 15.97% year-on-year, with a net profit attributable to shareholders of 229 million yuan, down 15.23% [6]. Group 2 - The company aims to enhance its core competitiveness through innovation and quality, focusing on high-quality development and optimizing its product mix to meet market demands [2][3]. - The company has over 100 ongoing research projects, targeting various therapeutic areas including oncology and cardiovascular diseases, to build a complementary product portfolio [5]. - The company emphasizes a diversified sales model, leveraging both policy responsiveness and resource integration to maintain revenue and profit sustainability amid industry price pressures [6][7]. Group 3 - The company has implemented a comprehensive employee training program to ensure high-quality development, focusing on talent cultivation and management [7]. - The company has established an audit committee for internal control and risk management, ensuring effective oversight of its subsidiaries [8]. - The company's 2020 equity incentive plan has been fully implemented [9].